[A NEW APPROACH TO TREATMENT LIVER CIRRHOSIS IN CONNECTION WITH INTESTINAL DYSBIOSIS]

Area of Science:

• Gastroenterology and Hepatology
• Microbiology
• Internal Medicine

Background:

• Liver cirrhosis is a significant health concern with complex treatment challenges.
• Intestinal microbiocenosis alterations are implicated in the progression of liver disease.
• Optimizing treatment strategies for liver cirrhosis remains a critical medical need.

Purpose of the Study:

• To evaluate the efficacy of incorporating synbiotic medications, specifically
• Bifilakt extra
• into the combined treatment of liver cirrhosis.
• To assess the impact of this synbiotic intervention on intestinal microbiocenosis and clinical outcomes.

Main Methods:

• A study involving 65 patients diagnosed with liver cirrhosis.
• Inclusion of the synbiotic medication
• Bifilakt extra
• into the standard combined treatment regimen.
• Monitoring of intestinal microbiocenosis features and clinical manifestations.

Main Results:

• The combined treatment including
• Bifilakt extra
• demonstrated a probable positive effect on reducing subjective and objective signs of liver cirrhosis.
• A notable reduction in the intensity of functional biochemical syndromes was observed.
• Symptoms associated with hepatic encephalopathy showed improvement with the synbiotic intervention.

Conclusions:

• Synbiotic medication
• Bifilakt extra
• appears to be a beneficial addition to the combined treatment of liver cirrhosis.
• This intervention may improve the overall effectiveness of cirrhosis management by positively influencing the gut microbiome.
• Further research is warranted to confirm these findings and elucidate the precise mechanisms of action.